They are inhibitors of one or more FGFR enzymes and are useful in the treatment of diseases associated with FGFR such as cancer. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt thereof, characterized in that: W is NR⁹,O o CR RRing a is a remaining formula (2)(3)(4) (5)X is CR1 830909 or N； y is nr.18310；O. O, O, s； Z is n or CH； Q absent, O, no.8310； 7491；o CR Rn is 0 or 1, where when n is 0 then Q is not absent； R¹ is H, NRARB, halo, and C₁₋₃ alkyl；R2 and R3 were selected from h, CN, C (o) n758080 and r74966, respectively；and C₁₋₇ alkyl,wherein said C₁₋₇ alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, ORᵃ,Cn, No. 7580； r74966；C (o) No. 7580； r74966；or R² and R³ together with the carbon atom to which they are attached form a 3-7 element cycloalkyl ring or a 4-7 element heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C₁₋₆ alkyl,C₁₋₆ haloalkyl,CN, ORᵃ,SR7491,C (O) RC (o) No. 7580； r74966；C (O) OROC (O) ROC (O) NR RNo. 7580； No. 74966；No. 7580； C (o) r7495；b. 7580 and C (o) or 74919；R830808,R83099,R8310,R8311th,and R⁸ are each independently selected from H, halo, C₁₋₆ alkyl,C₂₋₆ alkenyl,1. C 83228331 asphalt；C₁₋₆ haloalkyl,aryl C₆₋₁₀,C₃₋₁₀ cycloalkyl,Isomerization of 5-10, 4-10, CN, or7491；SRᵃ¹,C (O) RC (O) NR RC (O) OROC (O) ROC (O) NR RNR RNo. 7580；； 1 C (o) r7495；； 1No. 7580； 1 C (o) or7491； 1,NR C (O) NR RC (3DNR) RC (3DNR) NR RNR C (3DNR) NR RNR S (O) RNR S (O) RNR S (O) NR RS (O) RS (O) NR RS (O) Ry S (O) NR Rwherein said C alquilo alkyl,C₂₋₆ alkenyl,1. C 83228331 asphalt；aryl C₆₋₁₀,C₃₋₁₀ cycloalkyl,a. The isomers of 5-10 elements and 4-10 elements are replaced by c832131 tar, one, two, three, four or five selected substitutes without halogen；C₂₋₆ alkenyl,1. C 83228331 asphalt；C₁₋₆ haloalkyl,CN, NO₂,ORᵃ¹,SRᵃ¹,C (O) RC (O) NR RC (O) OROC (O) ROC (O) NR RC (3DNR) NR RNR C (3DNR) NR RNR RNo. 7580；； 1 C (o) r7495；； 1No. 7580； 1 C (o) o
